Provention Bio, Inc. Common Stock
PRVB
PRVB was delisted on the 26th of April, 2023.
9 hedge funds and large institutions have $3.42M invested in Provention Bio, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 9 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.82M |
| 2 |
DIM
DC Investments Management
Mclean,
Virginia
|
+$162K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$139K |
| 4 |
Goldman Sachs
New York
|
+$86.6K |
| 5 |
BlackRock
New York
|
+$82.1K |
Top Sellers
PRVB Hedge Fund Activity: Q3 2018 in Review
9 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q3 2018, worth a combined $3.42M.
Buyers outnumbered sellers: 9 funds opened new PRVB positions and 0 closed out — a net gain of 9 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $2.82M.
- 9 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q3 2018, up from 0 in Q2 2018.
- Funds reported $3.42M of Provention Bio, Inc. Common Stock stock for Q3 2018.
- 9 funds opened new Provention Bio, Inc. Common Stock positions in Q3 2018 and 0 closed out, a net change of +9 holders.
- The largest Provention Bio, Inc. Common Stock buyer in Q3 2018 was Vanguard Group, an estimated $2.82M added.
Based on aggregated 13F filings for Q3 2018.